Gastrointestinal mesenchymal tumors are the most common mesenchymal-derived tumors of the GI tract, accounting for 1%-3% of GI tumors, of which 60%-70% occur in the stomach, with the upper part of the stomach being the most common. Surgery has long been the first and only treatment with curative potential for patients with gastrointestinal mesenchymal tumors. The aim of surgery is to try to achieve complete resection of the tumor and avoid tumor rupture and intraoperative dissemination, and since lymph node metastasis from gastrointestinal mesenchymal tumor is rare, routine lymph node dissection is not recommended. For surgical treatment of gastric mesenchymal tumor for asymptomatic patients with diameter <2 cm, surgery should be selected according to whether it is combined with border irregularity, ulcer, strong echogenicity and heterogeneity under endoscopy or endoscopic ultrasound, and surgery should be considered for those with the above factors and tumor enlargement during follow-up; for resectable gastric mesenchymal tumor with diameter >2 cm, surgery is recommended, and according to the specific location, size, tumor For resectable gastric mesenchymal tumors >2 cm in diameter, surgery is recommended. The surgical procedures include partial or wedge resection, proximal gastrectomy, distal gastrectomy, total gastrectomy, and combined organ resection. In addition, for unresectable primary, metastatic or recurrent cases, targeted drug therapy first, followed by surgical treatment to assess resectability is the recommended model. Targeted drugs such as imatinib, sunitinib, regorafenib, etc.